Amicus Therapeutics (FOLD) Tops Q1 EPS by 5c, Misses on Revenue
Amicus Therapeutics (NASDAQ: FOLD) reported Q1 EPS of $0.03, $0.05 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $125.25 million versus the consensus estimate of $136.65 million.
For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.